Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting

Incyte Corporation announced the presentation of final six-month clinical data from the dose ranging, placebo-controlled Phase IIa trial of its orally available janus kinase (JAK) inhibitor INCB28050 in patients with active rheumatoid arthritis (RA).

11 Nov 2010

4SC 2010 first nine months revenue decreases from EUR1.4 million to EUR0.8 million

4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced its financial results in accordance with International Financial Reporting Standards (IFRS) for the first nine months of 2010, which ended on 30 September 2010.

11 Nov 2010

Nplate reduces treatment failure and splenectomies in adults with chronic immune thrombocytopenia

Amgen Inc. today announced the publication of results from the first open-label study to compare Nplate® (romiplostim) treatment to standard of care therapies (SOC) in non-splenectomized adult patients with chronic immune thrombocytopenia (ITP). The study results, which were published today in the New England Journal of Medicine (NEJM), show that both the incidence of treatment failure and need for splenectomy were reduced among the Nplate-treated patients.

11 Nov 2010

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced additional positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

10 Nov 2010

Zalicus third quarter total revenue decreases to $1.2 million

"We made solid product development progress this quarter," commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. "We finalized our development plans for Synavive, and also related to Synavive, we were awarded a Therapeutic Discovery Project grant to help fund Synavive development going forward.

10 Nov 2010

Abbott presents results of 2 pivotal HUMIRA studies at American College of Rheumatology meeting

Today, Abbott presents results from a pooled analysis of two pivotal HUMIRA® (adalimumab) studies, which look at patients with early and long-standing moderate to severe rheumatoid arthritis (RA), at the American College of Rheumatology meeting in Atlanta.

10 Nov 2010

Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented key preclinical findings of the Company's novel oral anti-interferon, MPI-0485520, at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals, in Atlanta, Georgia.

10 Nov 2010

Preclinical data from Idera's autoimmune and inflammatory disease program presented at 74th ACR

Idera Pharmaceuticals, Inc. today announced two presentations of preclinical data from its autoimmune and inflammatory disease program at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR) in Atlanta, Georgia. One presentation is entitled "IMO-3100, a Toll-like Receptor (TLR) Antagonist, Suppresses TLR7- and TLR9-mediated Immune Responses in Non-human Primates" (#856).

10 Nov 2010

Special Surgery investigators to present future of clinical care at ACR annual meeting

Hospital for Special Surgery physicians who focus on lupus, scleroderma and related conditions are traveling from New York City to Atlanta this week to share their recent findings at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR).

10 Nov 2010

Immunologix partners with Genscript to develop human antibody therapeutics

Immunologix, Inc, a Charleston, SC biotechnology company and a leader in fully human therapeutic antibodies for a variety of diseases and GenScript, a contract research organization (CRO) based in Piscataway, NJ and the industry leader in bio-reagent services, assay development & screening, lead optimization, and antibody drug development, announced today that the companies have formed a strategic partnership to offer a complete platform for producing human antibody therapeutics.

10 Nov 2010

Phytomedics awarded $244,000 QTDP grant for development of RA drug

Phytomedics, Inc., a transformational healthcare company developing a novel portfolio of drugs and consumer products solely derived from plant sources, announced today that it has been awarded a grant in the amount of $244,000 under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of its lead product PMI-001 for Rheumatoid Arthritis. PMI-001 is presently in Phase 2b/3 development.

9 Nov 2010

Study finds lack of medication adherence among people with RA and lupus

People with rheumatic diseases don't take their medication on a regular basis, and this leads to poor outcomes in their disease treatment, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

Patients with germinal center-like structures face greater risk of developing non-Hodgkin's lymphoma

Biopsying the glands that produce saliva to test for germinal center-like formation when someone is diagnosed with primary Sjögren's Syndrome can predict later development of non-Hodgkin's lymphoma, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

REF donates $24 million in innovative RA research

The American College of Rheumatology Research and Education Foundation today announced it has raised nearly $28 million, and funded $24 million, in RA research through its Within Our Reach: Finding a Cure for Rheumatoid Arthritis campaign - putting the Foundation two million from its initial $30 million goal.

9 Nov 2010

DHA protects brain tissue and promotes recovery in acute ischemic stroke

Research led by Dr. Nicolas Bazan, Boyd Professor, Villere Chair, and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center, has shown that Docosahexaenoic acid (DHA), a component of fish oil, is a powerful therapeutic agent that can protect brain tissue and promote recovery in an experimental model of acute ischemic stroke, even when treatment is delayed by up to five hours.

9 Nov 2010

ORAL Solo Phase 3 study shows tasocitinib reduces signs and symptoms of active RA

Pfizer Inc. today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean change in HAQ-DI, respectively, versus placebo at three months.

9 Nov 2010

Combination treatment with methotrexate and prednisone achieves remission in newly-developed RA

People with newly-developed rheumatoid arthritis or undifferentiated arthritis may be able to achieve remission, with continued drug therapy, after four months of treatment with methotrexate and prednisone, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

SIMPONI injection improves inflammation, structural damage in RA patients

Magnetic resonance imaging (MRI) analyses from two Phase 3 clinical trials showed that once every four week subcutaneous injections of SIMPONI (golimumab) 50 mg plus methotrexate resulted in statistically significant improvements in markers of inflammation and structural damage in patients with active rheumatoid arthritis (RA) compared with placebo plus methotrexate.

9 Nov 2010

Vaccinations do not increase risk of RA

Common adult vaccinations are not associated with an increased risk of developing rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

Anti-TNF therapy increases risk of varicella zoster virus infections

Anti tumor necrosis factor therapy increases the risk of developing varicella zoster virus infections, including shingles and chicken pox, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting

4SC 2010 first nine months revenue decreases from EUR1.4 million to EUR0.8 million

Nplate reduces treatment failure and splenectomies in adults with chronic immune thrombocytopenia

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

Zalicus third quarter total revenue decreases to $1.2 million

Abbott presents results of 2 pivotal HUMIRA studies at American College of Rheumatology meeting

Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting

Preclinical data from Idera's autoimmune and inflammatory disease program presented at 74th ACR

Special Surgery investigators to present future of clinical care at ACR annual meeting

Immunologix partners with Genscript to develop human antibody therapeutics

Phytomedics awarded $244,000 QTDP grant for development of RA drug

Study finds lack of medication adherence among people with RA and lupus

Patients with germinal center-like structures face greater risk of developing non-Hodgkin's lymphoma

REF donates $24 million in innovative RA research

DHA protects brain tissue and promotes recovery in acute ischemic stroke

ORAL Solo Phase 3 study shows tasocitinib reduces signs and symptoms of active RA

Combination treatment with methotrexate and prednisone achieves remission in newly-developed RA

SIMPONI injection improves inflammation, structural damage in RA patients

Vaccinations do not increase risk of RA

Anti-TNF therapy increases risk of varicella zoster virus infections

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in